Taika Capital’s United Therapeutics UTHR Stock Holding History

Taika Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,600	Closed	-$3.07M	–	65
2023 Q3	$3.07M	Buy	+13,600	New	+$3.13M	1.46%	32

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Taika Capital's UTHR Position: Q4 2023 in Review

Taika Capital sold out of United Therapeutics (UTHR) in Q4 2023, closing a stake of 13,600 shares — an estimated $3.07M sold.

Taika Capital first reported a position in UTHR in Q3 2023 and held it in 1 quarter. The position peaked at $3.07M in Q3 2023. 535 funds tracked by Wall St. Rank hold UTHR as of Q4 2023.

Taika Capital reported no remaining United Therapeutics position as of Q4 2023 after selling out during the quarter.
Taika Capital sold 13,600 United Therapeutics shares in Q4 2023, an estimated $3.07M.
Taika Capital first reported a position in United Therapeutics in Q3 2023 and held it in 1 quarter.
Taika Capital's United Therapeutics position peaked at $3.07M in Q3 2023.
535 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2023.

Based on Taika Capital's 13F filing for Q4 2023, filed 14 Feb 2024.